Sato Junya, Terui Kazufumi, Hayakari Makoto
Dept. of Pharmacy, Hirosaki University Hospital.
Gan To Kagaku Ryoho. 2009 Jul;36(7):1125-9.
Oxaliplatin therapy is a standard treatment for advanced colorectal cancer, and oxaliplatin hypersensitivity is one of its side effects that should be particularly considered. In the present study, we observed a decrease in the incidence of oxaliplatin hypersensitivity since the introduction of preliminary medication involving the administration of escalated doses of steroids and the use of antihistamine agents. From the medical economics perspective, although the costs of the preliminary medication were generated, those for the treatment of oxaliplatin hypersensitivity, which were higher than the total cost of the preliminary medication, needed to be generated for all patients. Introduction of preliminary medication decreased the overall cost, since the medication decreased the incidence of hypersensitivity. Therefore, preliminary medication was recognized to be effective from the perspective of medical economics. The preliminary medication we introduced contributed to a safe, cost-effective, and high-quality treatment for advanced colorectal cancer by preventing oxaliplatin hypersensitivity.
奥沙利铂疗法是晚期结直肠癌的标准治疗方法,奥沙利铂超敏反应是其应特别考虑的副作用之一。在本研究中,我们观察到自从引入涉及递增剂量类固醇给药和使用抗组胺药的预处理药物后,奥沙利铂超敏反应的发生率有所下降。从医学经济学角度来看,虽然产生了预处理药物的费用,但所有患者都需要产生用于治疗奥沙利铂超敏反应的费用,而该费用高于预处理药物的总费用。预处理药物的引入降低了总体成本,因为该药物降低了超敏反应的发生率。因此,从医学经济学角度来看,预处理药物被认为是有效的。我们引入的预处理药物通过预防奥沙利铂超敏反应,为晚期结直肠癌提供了安全、具有成本效益且高质量的治疗。